FMCG major Dabur India Ltd acquired Ajanta Pharma Ltd's energiser brand 30 Plus. The acquisition is expected to strengthen the FMCG company's position in the healthcare over-the-counter (OTC) space.
“The acquisition of 30 Plus is part of an aggressive strategy to build capability on the OTC healthcare business and I am confident that this transaction will help us in our endeavour to further strengthen our position in this category,” said Mr P.D. Narang, Group Director, Dabur India.
PricewaterhouseCoopers was the advisors to the deal.
Dabur has identified the healthcare OTC segment as an important growth area and has planned a number of initiatives going forward.
Synergies from this deal are expected to help Dabur expand its portfolio and capitalise on the emerging opportunities in the domestic as well as international markets, said Mr Narang.
30 Plus is an energiser brand targeted towards males in the 30-plus age group.